{
    "clinical_study": {
        "@rank": "25199", 
        "arm_group": {
            "arm_group_label": "CellCept", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in\n      combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and\n      steroids, in patients receiving a heart transplant. The anticipated time on study treatment\n      is 24 weeks."
        }, 
        "brief_title": "A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.", 
        "completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "condition": "Heart Transplantation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients, >=18 years of age;\n\n          -  patients receiving their first heart transplant (single organ transplant).\n\n        Exclusion Criteria:\n\n          -  patients with a positive donor-specific cross-match at the time of transplantation;\n\n          -  patients with any antibody-treated acute rejection;\n\n          -  known contraindications to treatment with sirolimus;\n\n          -  history of malignancy, other than excised non-melanoma skin cancer which has not\n             recurred for 2 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091414", 
            "org_study_id": "ML20055"
        }, 
        "intervention": [
            {
                "arm_group_label": "CellCept", 
                "description": "1.5 - 2.0 g orally daily", 
                "intervention_name": "mycophenolate mofetil [CellCept]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CellCept", 
                "description": "standard doses", 
                "intervention_name": "cyclosporine A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CellCept", 
                "description": "Type and dose determined by each study center", 
                "intervention_name": "corticosteroids", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Mycophenolic Acid", 
                "Mycophenolate mofetil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100029"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China", 
                        "zip": "350001"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200032"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Study to Evaluate the Effect of CellCept in Combination With Cyclosporine A and Steroids on Renal Function and the Prevention of Acute Rejection in Heart Transplant Patients.", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration of China (CFDA)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of acute rejection or hemodynamic compromise (HDC)", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091414"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of graft loss", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Renal function assessed  by serum creatinine (SCr)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2006", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}